5α-Reductase Type 2 Gene Variant Associations with Prostate Cancer Risk, Circulating Hormone Levels, and Androgenetic Alopecia

    November 2006 in “ International Journal of Cancer ”
    Vanessa M. Hayes, Gianluca Severi, Emma J.D. Padilla … Graham G. Giles
    Studysummary This study found that the SRD5A2 A49T A variant is associated with an increased risk of prostate cancer, lower circulating 3α‐diolG levels, and a decreased risk of baldness.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. The E211 G>A Androgen Receptor Polymorphism Is Associated With a Decreased Risk of Metastatic Prostate Cancer and Androgenetic Alopecia Cancer Epidemiology, Biomarkers & Prevention · 2005
    2. Polymorphism of the Androgen Receptor Gene Is Associated with Male Pattern Baldness Journal of Investigative Dermatology · 2001
    3. The Genetics of Androgenetic Alopecia Clinics in Dermatology · 2001
    4. Genetic Analysis of Male Pattern Baldness and the 5α-Reductase Genes Journal of Investigative Dermatology · 1998
    5. PNU 157706, A Novel Dual Type I and II 5α-Reductase Inhibitor The Journal of Steroid Biochemistry and Molecular Biology · 1998